Skip to main content

Journal of Cancer Research and Clinical Oncology

Ausgabe 3/2017

Inhalt (19 Artikel)

Review – Cancer Research

Current status in cancer cell reprogramming and its clinical implications

Kenan Izgi, Halit Canatan, Banu Iskender

Original Article – Cancer Research

HOXB8 promotes tumor metastasis and the epithelial–mesenchymal transition via ZEB2 targets in gastric cancer

Wen-Jin Ding, Min Zhou, Mei-Mei Chen, Chun-Ying Qu

Open Access Original Article – Cancer Research

A specific mode of microsatellite instability is a crucial biomarker in adult T-cell leukaemia/lymphoma patients

Kaname Miyashita, Kei Fujii, Kenichi Taguchi, Mototsugu Shimokawa, Mitsuaki A. Yoshida, Yasunobu Abe, Jun Okamura, Shinya Oda, Naokuni Uike

Original Article – Cancer Research

Risk factors for intestinal metaplasia in a southeastern Chinese population: an analysis of 28,745 cases

Jian-Xia Jiang, Qing Liu, Bing Zhao, Hai-Han Zhang, Huai-Ming Sang, Soyfoo-Muhammad Djaleel, Guo-Xin Zhang, Shun-Fu Xu

Original Article – Cancer Research

53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM–CHK2–P53 pathway

Jing Yao, Ai Huang, Xiumei Zheng, Tao Liu, Zhenyu Lin, Sheng Zhang, Qin Yang, Tao Zhang, Hong Ma

Original Article – Cancer Research

Expression of PIWIL3 in primary and metastatic melanoma

Thilo Gambichler, Christina Kohsik, Ann-Kathrin Höh, Kerstin Lang, Heiko U. Käfferlein, Thomas Brüning, Eggert Stockfleth, Markus Stücker, Max Dreißigacker, Michael Sand

Original Article – Cancer Research

Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma

Thomas M. Atkinson, Jennifer L. Hay, Alexander Shoushtari, Yuelin Li, Daniel J. Paucar, Sloane C. Smith, Ragini R. Kudchadkar, Austin Doyle, Jeffrey A. Sosman, Jorge Fernando Quevedo, Mohammed M. Milhem, Anthony M. Joshua, Gerald P. Linette, Thomas F. Gajewski, Jose Lutzky, David H. Lawson, Christopher D. Lao, Patrick J. Flynn, Mark R. Albertini, Takami Sato, Karl Lewis, Brian Marr, David H. Abramson, Mark Andrew Dickson, Gary K. Schwartz, Richard D. Carvajal

Original Article – Cancer Research

BRAF V600E-dependent role of autophagy in uveal melanoma

Yinu Zhao, Weibin Wang, Irene Min, Brian Wyrwas, Maureen Moore, Rasa Zarnegar, Thomas J. Fahey III

Review – Clinical Oncology

Detection of vertebral metastases: a meta-analysis comparing MRI, CT, PET, BS and BS with SPECT

Tao Liu, Shenghao Wang, Hao Liu, Bin Meng, Feng Zhou, Fan He, Xiaojian Shi, Huilin Yang

Original Article – Clinical Oncology

Therapeutic role of axillary lymph node dissection in patients with stage IV breast cancer: a population-based analysis

San-Gang Wu, Feng-Yan Li, Yue Chen, Jia-Yuan Sun, Huan-Xin Lin, Qin Lin, Zhen-Yu He

Original Article – Clinical Oncology

Sentinel lymph node mapping in patients with stage I endometrial carcinoma: a focus on bilateral mapping identification by comparing radiotracer Tc99m with blue dye versus indocyanine green fluorescent dye

Andrea Papadia, Ignacio Zapardiel, Beatrice Bussi, Fabio Ghezzi, Marcello Ceccaroni, Elena De Ponti, Federica Elisei, Sara Imboden, Begoña Diaz de la Noval, Maria Luisa Gasparri, Giampaolo Di Martino, Javier De Santiago, Michael Mueller, Francesca Vecchione, Federica Dell’Orto, Alessandro Buda

Original Article – Clinical Oncology

Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results

Zhongzhi Jia, Ricardo Paz-Fumagalli, Gregory Frey, David M. Sella, J. Mark McKinney, Weiping Wang

Original Article – Clinical Oncology

Presence of sarcomatoid differentiation as a prognostic indicator for survival in surgically treated metastatic renal cell carcinoma

Liangyou Gu, Hongzhao Li, Hanfeng Wang, Xin Ma, Lei Wang, Luyao Chen, Wenlei Zhao, Yu Zhang, Xu Zhang

Original Article – Clinical Oncology

Survival of de novo stage IV breast cancer patients over three decades

Dieter Hölzel, Renate Eckel, Ingo Bauerfeind, Bernd Baier, Thomas Beck, Michael Braun, Johannes Ettl, Ulrich Hamann, Nadia Harbeck, Marion Kiechle, Sven Mahner, Christian Schindlbeck, Johann de Waal, Jutta Engel

Original Article – Clinical Oncology

Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patients’ prognosis

Theodoros Tokas, Margaritis Avgeris, Christos Alamanis, Andreas Scorilas, Konstantinos G. Stravodimos, Constantinos A. Constantinides

Original Article – Clinical Oncology

Improvement of overall survival in stage IV melanoma patients during 2011–2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR)

Andrea Forschner, Felizitas Eichner, Teresa Amaral, Ulrike Keim, Claus Garbe, Thomas Kurt Eigentler

Open Access Original Article – Clinical Oncology

A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO)

Jalid Sehouli, Oliver Tomè, Desislava Dimitrova, Oumar Camara, Ingo Bernhard Runnebaum, Hans Werner Tessen, Beate Rautenberg, Radoslav Chekerov, Mustafa Zelal Muallem, Michael Patrick Lux, Tanja Trarbach, Gerald Gitsch

Letter to the Editor

Plasma microRNA-103, microRNA-107, and microRNA-194 levels are not biomarkers for human diffuse gastric cancer

Isao Oze, Shu Shimada, Hiromi Nagasaki, Yoshimitsu Akiyama, Miki Watanabe, Yasushi Yatabe, Keitaro Matsuo, Yasuhito Yuasa

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.